Clinical Trial

A 44-week Monocentric Open Study Assessing the Efficacy and Safety of Deucravacitinib in Adults With Inflammatory Genodermatoses

Study acronym: GENEPID
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 5, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to learn about deucravacitinib treatment in adults with inflammatory epidermal genodermatoses . The main question it aims to answer are: describe efficacity and safety of this treatment. Participants will take treatments and have to use bullets during the study period.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-11-13; most recent amendment 2025-07-31.
Status change: Not Yet Recruiting → Recruiting 2024-10-18
Trial Details
NCT Number NCT06136403
Lead Sponsor Centre Hospitalier Universitaire de Nice
Conditions Epidermolysis Bullosa Simplex, Ichthyosis, Genodermatosis, Inflammatory Congenital Ichthyoses
Enrollment 10 participants
Start Date 2024-03-18
Primary Completion 2025-09-30 (estimated)
Study Completion 2026-10-12 (estimated)
Updated on ClinicalTrials.gov 2025-08-05